Mesut Savas1,2, Taulant Muka3, Vincent L Wester1,2, Erica L T van den Akker2,4, Jenny A Visser1,2, Gert-Jan Braunstahl5,6, Sandra N Slagter7, Bruce H R Wolffenbuttel7, Oscar H Franco3, Elisabeth F C van Rossum1,2. 1. Internal Medicine, Division of Endocrinology, Erasmus MC, University Medical Center Rotterdam, 3000 CA Rotterdam, Netherlands. 2. Obesity Center CGG (Centrum Gezond Gewicht), Erasmus MC, University Medical Center Rotterdam, 3000 CA Rotterdam, Netherland. 3. Epidemiology, Erasmus MC, University Medical Center Rotterdam, 3000 CA Rotterdam, Netherlands. 4. Pediatrics, Erasmus MC, University Medical Center Rotterdam, 3000 CA Rotterdam, Netherlands. 5. Pulmonology, Erasmus MC, University Medical Center Rotterdam, 3000 CA Rotterdam, Netherlands. 6. Pulmonology, Sint Franciscus Gasthuis, 3045 PM Rotterdam, Netherlands. 7. Endocrinology, University of Groningen, University Medical Center Groningen, 9700 RB Groningen, Netherlands.
Abstract
Context: Use of systemic corticosteroids (CSs) may induce adverse cardiometabolic alterations, potentially leading to obesity and metabolic syndrome (MetS). Although evidence is accumulating that local CSs have considerable systemic effects, their effects on cardiometabolic factors in the general population remain unclear. Objective: To investigate the association between overall CS use and specific CS types with MetS, body mass index (BMI), and other cardiometabolic traits. Design: Cross-sectional cohort study. Setting: General population from the northern Netherlands. Participants: A total of 140,879 adult participants in the population-based Lifelines Cohort Study. Main Outcome Measures: BMI, waist circumference, systolic and diastolic blood pressure, fasting metabolic serum parameters, and a comprehensive set of potential confounding factors. Results: In women, overall, systemic, and local CS use was associated with higher odds of having MetS. Among local female users, only nasal (odds ratio [OR], 1.20 [95% confidence interval (CI), 1.06 to 1.36]) and inhaled CSs [OR, 1.35 (95% CI, 1.24 to 1.49)] users were more likely to have MetS. In men, no association was found between overall and specific CS use and presence of MetS. Use of local-only CSs in women, specifically inhaled CSs in both sexes, was associated with higher BMI. Conclusions: Use of local CSs, particularly inhaled types, as well as systemic CSs, was associated with higher likelihood of having MetS, higher BMI, and other adverse cardiometabolic traits, especially among women. Because the inhaled agents are the main group of prescribed CSs, this might be a substantial risk to public health in case of a yet-to-be-proven causal relationship.
Context: Use of systemic corticosteroids (CSs) may induce adverse cardiometabolic alterations, potentially leading to obesity and metabolic syndrome (MetS). Although evidence is accumulating that local CSs have considerable systemic effects, their effects on cardiometabolic factors in the general population remain unclear. Objective: To investigate the association between overall CS use and specific CS types with MetS, body mass index (BMI), and other cardiometabolic traits. Design: Cross-sectional cohort study. Setting: General population from the northern Netherlands. Participants: A total of 140,879 adult participants in the population-based Lifelines Cohort Study. Main Outcome Measures: BMI, waist circumference, systolic and diastolic blood pressure, fasting metabolic serum parameters, and a comprehensive set of potential confounding factors. Results: In women, overall, systemic, and local CS use was associated with higher odds of having MetS. Among local female users, only nasal (odds ratio [OR], 1.20 [95% confidence interval (CI), 1.06 to 1.36]) and inhaled CSs [OR, 1.35 (95% CI, 1.24 to 1.49)] users were more likely to have MetS. In men, no association was found between overall and specific CS use and presence of MetS. Use of local-only CSs in women, specifically inhaled CSs in both sexes, was associated with higher BMI. Conclusions: Use of local CSs, particularly inhaled types, as well as systemic CSs, was associated with higher likelihood of having MetS, higher BMI, and other adverse cardiometabolic traits, especially among women. Because the inhaled agents are the main group of prescribed CSs, this might be a substantial risk to public health in case of a yet-to-be-proven causal relationship.
Authors: Mesut Savas; Christiaan H Vinkers; Judith G M Rosmalen; Catharina A Hartman; Vincent L Wester; Erica L T van den Akker; Anand M Iyer; Bruce S McEwen; Elisabeth F C van Rossum Journal: Neuroendocrinology Date: 2019-06-21 Impact factor: 4.914
Authors: Kim Han; An Nguyen; Javier Traba; Xianglan Yao; Maryann Kaler; Rebecca D Huffstutler; Stewart J Levine; Michael N Sack Journal: J Immunol Date: 2018-07-18 Impact factor: 5.422
Authors: Robin Lengton; Anand M Iyer; Eline S van der Valk; Ellen K Hoogeveen; Onno C Meijer; Bibian van der Voorn; Elisabeth F C van Rossum Journal: Obes Rev Date: 2021-11-27 Impact factor: 10.867
Authors: Eline S van der Valk; Erica L T van den Akker; Mesut Savas; Lotte Kleinendorst; Jenny A Visser; Mieke M Van Haelst; Arya M Sharma; Elisabeth F C van Rossum Journal: Obes Rev Date: 2019-03-01 Impact factor: 9.213
Authors: Jasper H Kappen; Elisabeth F C van Rossum; Jan A Witte; Gert-Jan Braunstahl; Wouter J B Blox; Susan C van 't Westeinde; Johannes C C M In 't Veen Journal: BMC Pulm Med Date: 2022-02-05 Impact factor: 3.317